Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Opko Health, Inc. is a diversified healthcare company operating across the pharmaceuticals and diagnostics industries, with a focus on developing, acquiring, and commercializing novel therapies and advanced diagnostic technologies. The company’s activities span drug development, clinical laboratory services, and proprietary diagnostic tests, positioning it at the intersection of precision medicine and specialty healthcare services.
The company’s primary revenue drivers are its diagnostics operations, led by BioReference Laboratories, and its pharmaceutical products, most notably Rayaldee (calcifediol) for the treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease. Opko Health serves hospitals, physicians, health systems, life sciences companies, and managed care organizations, with a strategic emphasis on differentiated diagnostics and specialty pharmaceuticals. Founded in 1996, Opko Health evolved from an early-stage pharmaceutical developer into a diversified healthcare platform through acquisitions, internal development, and international expansion.
Business Operations
Opko Health operates primarily through two reportable segments: Diagnostics and Pharmaceuticals. The Diagnostics segment is anchored by BioReference Laboratories, one of the largest full-service clinical laboratories in the United States, offering routine and esoteric testing, genomics, oncology diagnostics, and clinical trial laboratory services. This segment generates the majority of the company’s revenue and includes proprietary diagnostic products such as the 4Kscore Test, used to assess prostate cancer risk.
The Pharmaceuticals segment focuses on the development and commercialization of specialty therapies. Key assets include Rayaldee and a pipeline of drug candidates targeting renal disease, endocrinology, infectious disease, and oncology. Opko Health also controls ModeX Therapeutics, a biotechnology subsidiary focused on next-generation immunotherapies and vaccines. Operations include both domestic and international pharmaceutical sales, supported by in-house research capabilities and external manufacturing and commercialization partners.
Strategic Position & Investments
Opko Health’s strategy centers on leveraging its scale in diagnostics to generate stable cash flow while selectively investing in higher-growth pharmaceutical and biotechnology opportunities. The company has emphasized portfolio optimization, cost management, and the advancement of proprietary assets with clear regulatory and commercial pathways. The acquisition of ModeX Therapeutics expanded Opko Health’s exposure to emerging technologies in antibody engineering and immune modulation.
Strategic investments also include continued development of diagnostic innovations within BioReference Laboratories and targeted pharmaceutical development programs addressing unmet medical needs. Opko Health has historically pursued partnerships and licensing arrangements to share development risk and extend market reach, although the scope and financial impact of certain collaborations are not consistently detailed across public disclosures. Where disclosures differ, data inconclusive based on available public sources.
Geographic Footprint
Opko Health is headquartered in Miami, Florida, with its largest operational footprint in the United States, where the majority of diagnostic testing and pharmaceutical revenues are generated. BioReference Laboratories operates an extensive national laboratory network serving healthcare providers across multiple states.
Internationally, Opko Health maintains pharmaceutical operations and investments in Latin America, Europe, and Israel, with commercial activities in markets such as Spain, Mexico, Chile, and Israel. These international operations support both marketed products and development-stage assets, providing geographic diversification and access to non-U.S. growth opportunities.
Leadership & Governance
Opko Health was founded by Phillip Frost, who continues to play a central role in shaping the company’s long-term strategy. Leadership emphasizes opportunistic acquisition, scientific innovation, and disciplined capital allocation, reflecting a governance approach led closely by senior executives and the board.
Key executives include:
- Phillip Frost – Chairman and Chief Executive Officer
- Adam Logal – Executive Vice President and Chief Financial Officer
- Robert S. Weisel – Chief Executive Officer, BioReference Laboratories
- Ephraim Grinberg – Chief Executive Officer, OPKO Health Europe
Where executive roles or titles vary across reporting periods, information reflects the most consistently reported positions in public filings; discrepancies, if any, are not material based on available public sources.